Recon: Pfizer’s Adcetris shows promise in phase 3 blood cancer study; FDA reviewers raise concerns about Geron's blood disorder drug
ReconJason Scott
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States